Mats Holmberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8562524/publications.pdf

Version: 2024-02-01

		1162367	940134	
16	484	8	16	
papers	citations	h-index	g-index	
17	17	17	501	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	Citations
1	Preferential location of X-ray induced chromosome breakage in the R-bands of human chromosomes. Hereditas, 2009, 74, 57-68.	0.5	123
2	Supporting sexuality and improving sexual function in transgender persons. Nature Reviews Urology, 2019, 16, 121-139.	1.9	66
3	Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey. Thyroid, 2019, 29. 322-331.	2.4	61
4	Muscle Strength, Size, and Composition Following 12 Months of Gender-affirming Treatment in Transgender Individuals. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e805-e813.	1.8	60
5	The Long-Term Outcome of Treatment for Graves' Hyperthyroidism. Thyroid, 2019, 29, 1545-1557.	2.4	55
6	Metabolic and functional changes in transgender individuals following cross-sex hormone treatment: Design and methods of the GEnder Dysphoria Treatment in Sweden (GETS) study. Contemporary Clinical Trials Communications, 2018, 10, 148-153.	0.5	27
7	Cross sex hormone treatment is linked with a reversal of cerebral patterns associated with gender dysphoria to the baseline of cisgender controls. European Journal of Neuroscience, 2019, 50, 3269-3281.	1.2	23
8	Evidence for an inverse relationship between X-ray induced chromatid and chromosome breakage in human chromosomes. Hereditas, 2009, 75, 259-266.	0.5	19
9	Predicting outcomes of cross-sex hormone therapy in transgender individuals with gender incongruence based on pre-therapy resting-state brain connectivity. Neurolmage: Clinical, 2021, 29, 102517.	1.4	14
10	Cardiovascular outcomes in transgender individuals in Sweden after initiation of gender-affirming hormone therapy. European Journal of Preventive Cardiology, 2022, 29, 2017-2026.	0.8	10
11			